ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ADMS Adamas Pharmaceuticals Inc

8.22
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Adamas Pharmaceuticals Inc NASDAQ:ADMS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 8.22 9.33 8.30 0 01:00:00

Adamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021

02/08/2021 9:02pm

Business Wire


Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart


From Jul 2021 to Jul 2024

Click Here for more Adamas Pharmaceuticals Charts.

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Investor Conference Call and Webcast

The conference call can be accessed by dialing 1-877-407-9716 for participants in the U.S. or Canada and 1-201-493-6779 for international callers. All callers must provide the following Conference ID: 13720109. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay for approximately 30 days.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Media: Sarah Mathieson Vice President of Corporate Communications 510-450-3528 smathieson@adamaspharma.com

Investors: Peter Vozzo Managing Director, Westwicke 443-213-0505 peter.vozzo@westwicke.com

1 Year Adamas Pharmaceuticals Chart

1 Year Adamas Pharmaceuticals Chart

1 Month Adamas Pharmaceuticals Chart

1 Month Adamas Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock